nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP2C8—Mometasone—systemic scleroderma	0.131	0.221	CbGbCtD
Cyclophosphamide—ABCB1—Lisinopril—systemic scleroderma	0.0601	0.101	CbGbCtD
Cyclophosphamide—CYP2C9—Leflunomide—systemic scleroderma	0.0591	0.0991	CbGbCtD
Cyclophosphamide—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0544	0.0913	CbGbCtD
Cyclophosphamide—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0523	0.0878	CbGbCtD
Cyclophosphamide—ABCB1—Captopril—systemic scleroderma	0.045	0.0755	CbGbCtD
Cyclophosphamide—CYP2D6—Captopril—systemic scleroderma	0.0424	0.0711	CbGbCtD
Cyclophosphamide—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0354	0.0594	CbGbCtD
Cyclophosphamide—CYP2C19—Prednisone—systemic scleroderma	0.0351	0.0589	CbGbCtD
Cyclophosphamide—ABCB1—Prednisone—systemic scleroderma	0.0283	0.0475	CbGbCtD
Cyclophosphamide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0212	0.0356	CbGbCtD
Cyclophosphamide—CYP3A4—Prednisone—systemic scleroderma	0.017	0.0285	CbGbCtD
Cyclophosphamide—ABCB1—Methotrexate—systemic scleroderma	0.0142	0.0238	CbGbCtD
Cyclophosphamide—Cough—Lisinopril—systemic scleroderma	0.000206	0.000509	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000204	0.000505	CcSEcCtD
Cyclophosphamide—Anorexia—Mycophenolic acid—systemic scleroderma	0.000204	0.000504	CcSEcCtD
Cyclophosphamide—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000202	0.0005	CcSEcCtD
Cyclophosphamide—Paraesthesia—Leflunomide—systemic scleroderma	0.000201	0.000497	CcSEcCtD
Cyclophosphamide—Chest pain—Lisinopril—systemic scleroderma	0.000201	0.000497	CcSEcCtD
Cyclophosphamide—Myalgia—Lisinopril—systemic scleroderma	0.000201	0.000497	CcSEcCtD
Cyclophosphamide—Arthralgia—Lisinopril—systemic scleroderma	0.000201	0.000497	CcSEcCtD
Cyclophosphamide—Dyspnoea—Leflunomide—systemic scleroderma	0.0002	0.000494	CcSEcCtD
Cyclophosphamide—Hypotension—Mycophenolic acid—systemic scleroderma	0.0002	0.000494	CcSEcCtD
Cyclophosphamide—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000198	0.000491	CcSEcCtD
Cyclophosphamide—Discomfort—Lisinopril—systemic scleroderma	0.000198	0.000491	CcSEcCtD
Cyclophosphamide—Vomiting—Mometasone—systemic scleroderma	0.000197	0.000487	CcSEcCtD
Cyclophosphamide—Sweating increased—Prednisone—systemic scleroderma	0.000196	0.000484	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Azathioprine—systemic scleroderma	0.000195	0.000483	CcSEcCtD
Cyclophosphamide—Rash—Mometasone—systemic scleroderma	0.000195	0.000482	CcSEcCtD
Cyclophosphamide—Asthenia—Captopril—systemic scleroderma	0.000195	0.000482	CcSEcCtD
Cyclophosphamide—Dermatitis—Mometasone—systemic scleroderma	0.000195	0.000482	CcSEcCtD
Cyclophosphamide—Decreased appetite—Leflunomide—systemic scleroderma	0.000195	0.000482	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000195	0.000481	CcSEcCtD
Cyclophosphamide—Confusional state—Lisinopril—systemic scleroderma	0.000194	0.00048	CcSEcCtD
Cyclophosphamide—Headache—Mometasone—systemic scleroderma	0.000194	0.000479	CcSEcCtD
Cyclophosphamide—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000193	0.000479	CcSEcCtD
Cyclophosphamide—Fatigue—Leflunomide—systemic scleroderma	0.000193	0.000478	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000192	0.000476	CcSEcCtD
Cyclophosphamide—Oedema—Lisinopril—systemic scleroderma	0.000192	0.000476	CcSEcCtD
Cyclophosphamide—Pruritus—Captopril—systemic scleroderma	0.000192	0.000476	CcSEcCtD
Cyclophosphamide—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000192	0.000475	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000474	CcSEcCtD
Cyclophosphamide—Constipation—Leflunomide—systemic scleroderma	0.000191	0.000474	CcSEcCtD
Cyclophosphamide—Pain—Leflunomide—systemic scleroderma	0.000191	0.000474	CcSEcCtD
Cyclophosphamide—Infection—Lisinopril—systemic scleroderma	0.000191	0.000473	CcSEcCtD
Cyclophosphamide—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000472	CcSEcCtD
Cyclophosphamide—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00019	0.000471	CcSEcCtD
Cyclophosphamide—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00019	0.00047	CcSEcCtD
Cyclophosphamide—Shock—Lisinopril—systemic scleroderma	0.000189	0.000468	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000188	0.000466	CcSEcCtD
Cyclophosphamide—Tachycardia—Lisinopril—systemic scleroderma	0.000188	0.000465	CcSEcCtD
Cyclophosphamide—Body temperature increased—Azathioprine—systemic scleroderma	0.000187	0.000464	CcSEcCtD
Cyclophosphamide—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000461	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000186	0.00046	CcSEcCtD
Cyclophosphamide—Diarrhoea—Captopril—systemic scleroderma	0.000186	0.00046	CcSEcCtD
Cyclophosphamide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000186	0.000459	CcSEcCtD
Cyclophosphamide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000185	0.000457	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Leflunomide—systemic scleroderma	0.000184	0.000456	CcSEcCtD
Cyclophosphamide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000184	0.000456	CcSEcCtD
Cyclophosphamide—Nausea—Mometasone—systemic scleroderma	0.000184	0.000455	CcSEcCtD
Cyclophosphamide—Anorexia—Lisinopril—systemic scleroderma	0.000183	0.000454	CcSEcCtD
Cyclophosphamide—Weight increased—Prednisone—systemic scleroderma	0.000183	0.000452	CcSEcCtD
Cyclophosphamide—Constipation—Mycophenolic acid—systemic scleroderma	0.000183	0.000452	CcSEcCtD
Cyclophosphamide—Pain—Mycophenolic acid—systemic scleroderma	0.000183	0.000452	CcSEcCtD
Cyclophosphamide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000182	0.000452	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Prednisone—systemic scleroderma	0.000181	0.000448	CcSEcCtD
Cyclophosphamide—Cough—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000446	CcSEcCtD
Cyclophosphamide—Hypotension—Lisinopril—systemic scleroderma	0.00018	0.000445	CcSEcCtD
Cyclophosphamide—Dizziness—Captopril—systemic scleroderma	0.00018	0.000444	CcSEcCtD
Cyclophosphamide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000443	CcSEcCtD
Cyclophosphamide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000178	0.000441	CcSEcCtD
Cyclophosphamide—Urticaria—Leflunomide—systemic scleroderma	0.000178	0.00044	CcSEcCtD
Cyclophosphamide—Body temperature increased—Leflunomide—systemic scleroderma	0.000177	0.000438	CcSEcCtD
Cyclophosphamide—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000177	0.000437	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000176	0.000435	CcSEcCtD
Cyclophosphamide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000435	CcSEcCtD
Cyclophosphamide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000435	CcSEcCtD
Cyclophosphamide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000435	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000176	0.000434	CcSEcCtD
Cyclophosphamide—Myocardial infarction—Prednisone—systemic scleroderma	0.000176	0.000434	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000175	0.000434	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000175	0.000433	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000175	0.000432	CcSEcCtD
Cyclophosphamide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000174	0.00043	CcSEcCtD
Cyclophosphamide—Paraesthesia—Lisinopril—systemic scleroderma	0.000173	0.000427	CcSEcCtD
Cyclophosphamide—Vomiting—Captopril—systemic scleroderma	0.000173	0.000427	CcSEcCtD
Cyclophosphamide—Dyspnoea—Lisinopril—systemic scleroderma	0.000171	0.000424	CcSEcCtD
Cyclophosphamide—Rash—Captopril—systemic scleroderma	0.000171	0.000424	CcSEcCtD
Cyclophosphamide—Dermatitis—Captopril—systemic scleroderma	0.000171	0.000423	CcSEcCtD
Cyclophosphamide—Headache—Captopril—systemic scleroderma	0.00017	0.000421	CcSEcCtD
Cyclophosphamide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00017	0.00042	CcSEcCtD
Cyclophosphamide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000169	0.000418	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000168	0.000417	CcSEcCtD
Cyclophosphamide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000168	0.000417	CcSEcCtD
Cyclophosphamide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000414	CcSEcCtD
Cyclophosphamide—Decreased appetite—Lisinopril—systemic scleroderma	0.000167	0.000414	CcSEcCtD
Cyclophosphamide—Fatigue—Lisinopril—systemic scleroderma	0.000166	0.00041	CcSEcCtD
Cyclophosphamide—Shock—Mycophenolate mofetil—systemic scleroderma	0.000166	0.00041	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000408	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000165	0.000408	CcSEcCtD
Cyclophosphamide—Pain—Lisinopril—systemic scleroderma	0.000164	0.000407	CcSEcCtD
Cyclophosphamide—Constipation—Lisinopril—systemic scleroderma	0.000164	0.000407	CcSEcCtD
Cyclophosphamide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000164	0.000407	CcSEcCtD
Cyclophosphamide—Bradycardia—Prednisone—systemic scleroderma	0.000164	0.000405	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000163	0.000403	CcSEcCtD
Cyclophosphamide—Diarrhoea—Azathioprine—systemic scleroderma	0.000162	0.000401	CcSEcCtD
Cyclophosphamide—Haemoglobin—Prednisone—systemic scleroderma	0.000162	0.0004	CcSEcCtD
Cyclophosphamide—Nausea—Captopril—systemic scleroderma	0.000161	0.000399	CcSEcCtD
Cyclophosphamide—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000161	0.000398	CcSEcCtD
Cyclophosphamide—Haemorrhage—Prednisone—systemic scleroderma	0.000161	0.000398	CcSEcCtD
Cyclophosphamide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000161	0.000398	CcSEcCtD
Cyclophosphamide—Asthenia—Leflunomide—systemic scleroderma	0.000161	0.000397	CcSEcCtD
Cyclophosphamide—Pancytopenia—Methotrexate—systemic scleroderma	0.000159	0.000395	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000158	0.000392	CcSEcCtD
Cyclophosphamide—Pruritus—Leflunomide—systemic scleroderma	0.000158	0.000392	CcSEcCtD
Cyclophosphamide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000157	0.00039	CcSEcCtD
Cyclophosphamide—Dizziness—Azathioprine—systemic scleroderma	0.000157	0.000388	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000154	0.00038	CcSEcCtD
Cyclophosphamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000153	0.000379	CcSEcCtD
Cyclophosphamide—Diarrhoea—Leflunomide—systemic scleroderma	0.000153	0.000379	CcSEcCtD
Cyclophosphamide—Urticaria—Lisinopril—systemic scleroderma	0.000153	0.000378	CcSEcCtD
Cyclophosphamide—Body temperature increased—Lisinopril—systemic scleroderma	0.000152	0.000376	CcSEcCtD
Cyclophosphamide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000151	0.000374	CcSEcCtD
Cyclophosphamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000151	0.000374	CcSEcCtD
Cyclophosphamide—Vomiting—Azathioprine—systemic scleroderma	0.000151	0.000373	CcSEcCtD
Cyclophosphamide—Pneumonia—Methotrexate—systemic scleroderma	0.000151	0.000373	CcSEcCtD
Cyclophosphamide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00015	0.000372	CcSEcCtD
Cyclophosphamide—Rash—Azathioprine—systemic scleroderma	0.000149	0.00037	CcSEcCtD
Cyclophosphamide—Dermatitis—Azathioprine—systemic scleroderma	0.000149	0.000369	CcSEcCtD
Cyclophosphamide—Flushing—Prednisone—systemic scleroderma	0.000149	0.000369	CcSEcCtD
Cyclophosphamide—Headache—Azathioprine—systemic scleroderma	0.000148	0.000367	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000148	0.000367	CcSEcCtD
Cyclophosphamide—Dizziness—Leflunomide—systemic scleroderma	0.000148	0.000366	CcSEcCtD
Cyclophosphamide—Renal failure—Methotrexate—systemic scleroderma	0.000147	0.000364	CcSEcCtD
Cyclophosphamide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000363	CcSEcCtD
Cyclophosphamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000146	0.000362	CcSEcCtD
Cyclophosphamide—Stomatitis—Methotrexate—systemic scleroderma	0.000146	0.000361	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Methotrexate—systemic scleroderma	0.000145	0.00036	CcSEcCtD
Cyclophosphamide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000357	CcSEcCtD
Cyclophosphamide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000357	CcSEcCtD
Cyclophosphamide—Arrhythmia—Prednisone—systemic scleroderma	0.000144	0.000355	CcSEcCtD
Cyclophosphamide—Sweating—Methotrexate—systemic scleroderma	0.000143	0.000355	CcSEcCtD
Cyclophosphamide—Haematuria—Methotrexate—systemic scleroderma	0.000143	0.000353	CcSEcCtD
Cyclophosphamide—Vomiting—Leflunomide—systemic scleroderma	0.000142	0.000352	CcSEcCtD
Cyclophosphamide—Alopecia—Prednisone—systemic scleroderma	0.000142	0.000352	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000142	0.000351	CcSEcCtD
Cyclophosphamide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000141	0.000349	CcSEcCtD
Cyclophosphamide—Rash—Leflunomide—systemic scleroderma	0.000141	0.000349	CcSEcCtD
Cyclophosphamide—Dermatitis—Leflunomide—systemic scleroderma	0.000141	0.000349	CcSEcCtD
Cyclophosphamide—Nausea—Azathioprine—systemic scleroderma	0.000141	0.000348	CcSEcCtD
Cyclophosphamide—Headache—Leflunomide—systemic scleroderma	0.00014	0.000347	CcSEcCtD
Cyclophosphamide—Erythema—Prednisone—systemic scleroderma	0.00014	0.000346	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Methotrexate—systemic scleroderma	0.00014	0.000346	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000139	0.000344	CcSEcCtD
Cyclophosphamide—Asthenia—Lisinopril—systemic scleroderma	0.000138	0.000341	CcSEcCtD
Cyclophosphamide—Pruritus—Lisinopril—systemic scleroderma	0.000136	0.000337	CcSEcCtD
Cyclophosphamide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000136	0.000336	CcSEcCtD
Cyclophosphamide—Haemoglobin—Methotrexate—systemic scleroderma	0.000135	0.000334	CcSEcCtD
Cyclophosphamide—Rash—Mycophenolic acid—systemic scleroderma	0.000135	0.000333	CcSEcCtD
Cyclophosphamide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000134	0.000333	CcSEcCtD
Cyclophosphamide—Haemorrhage—Methotrexate—systemic scleroderma	0.000134	0.000333	CcSEcCtD
Cyclophosphamide—Hepatitis—Methotrexate—systemic scleroderma	0.000134	0.000333	CcSEcCtD
Cyclophosphamide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000134	0.000331	CcSEcCtD
Cyclophosphamide—Headache—Mycophenolic acid—systemic scleroderma	0.000134	0.000331	CcSEcCtD
Cyclophosphamide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000133	0.00033	CcSEcCtD
Cyclophosphamide—Nausea—Leflunomide—systemic scleroderma	0.000133	0.000329	CcSEcCtD
Cyclophosphamide—Vision blurred—Prednisone—systemic scleroderma	0.000132	0.000326	CcSEcCtD
Cyclophosphamide—Diarrhoea—Lisinopril—systemic scleroderma	0.000132	0.000326	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Prednisone—systemic scleroderma	0.00013	0.000321	CcSEcCtD
Cyclophosphamide—Visual impairment—Methotrexate—systemic scleroderma	0.000129	0.00032	CcSEcCtD
Cyclophosphamide—Anaemia—Prednisone—systemic scleroderma	0.000129	0.00032	CcSEcCtD
Cyclophosphamide—Agitation—Prednisone—systemic scleroderma	0.000129	0.000318	CcSEcCtD
Cyclophosphamide—Dizziness—Lisinopril—systemic scleroderma	0.000127	0.000315	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000127	0.000314	CcSEcCtD
Cyclophosphamide—Nausea—Mycophenolic acid—systemic scleroderma	0.000127	0.000314	CcSEcCtD
Cyclophosphamide—Malaise—Prednisone—systemic scleroderma	0.000126	0.000312	CcSEcCtD
Cyclophosphamide—Tinnitus—Methotrexate—systemic scleroderma	0.000125	0.00031	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000307	CcSEcCtD
Cyclophosphamide—Vomiting—Lisinopril—systemic scleroderma	0.000122	0.000303	CcSEcCtD
Cyclophosphamide—Rash—Lisinopril—systemic scleroderma	0.000121	0.0003	CcSEcCtD
Cyclophosphamide—Convulsion—Prednisone—systemic scleroderma	0.000121	0.0003	CcSEcCtD
Cyclophosphamide—Dermatitis—Lisinopril—systemic scleroderma	0.000121	0.0003	CcSEcCtD
Cyclophosphamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000299	CcSEcCtD
Cyclophosphamide—Hypertension—Prednisone—systemic scleroderma	0.000121	0.000299	CcSEcCtD
Cyclophosphamide—Chills—Methotrexate—systemic scleroderma	0.000121	0.000298	CcSEcCtD
Cyclophosphamide—Headache—Lisinopril—systemic scleroderma	0.00012	0.000298	CcSEcCtD
Cyclophosphamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000295	CcSEcCtD
Cyclophosphamide—Arthralgia—Prednisone—systemic scleroderma	0.000119	0.000295	CcSEcCtD
Cyclophosphamide—Myalgia—Prednisone—systemic scleroderma	0.000119	0.000295	CcSEcCtD
Cyclophosphamide—Alopecia—Methotrexate—systemic scleroderma	0.000119	0.000294	CcSEcCtD
Cyclophosphamide—Discomfort—Prednisone—systemic scleroderma	0.000118	0.000291	CcSEcCtD
Cyclophosphamide—Erythema—Methotrexate—systemic scleroderma	0.000117	0.000289	CcSEcCtD
Cyclophosphamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000285	CcSEcCtD
Cyclophosphamide—Dysgeusia—Methotrexate—systemic scleroderma	0.000115	0.000283	CcSEcCtD
Cyclophosphamide—Nausea—Lisinopril—systemic scleroderma	0.000114	0.000283	CcSEcCtD
Cyclophosphamide—Oedema—Prednisone—systemic scleroderma	0.000114	0.000283	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Prednisone—systemic scleroderma	0.000114	0.000283	CcSEcCtD
Cyclophosphamide—Infection—Prednisone—systemic scleroderma	0.000113	0.000281	CcSEcCtD
Cyclophosphamide—Shock—Prednisone—systemic scleroderma	0.000112	0.000278	CcSEcCtD
Cyclophosphamide—Tachycardia—Prednisone—systemic scleroderma	0.000111	0.000276	CcSEcCtD
Cyclophosphamide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000276	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Prednisone—systemic scleroderma	0.00011	0.000273	CcSEcCtD
Cyclophosphamide—Vision blurred—Methotrexate—systemic scleroderma	0.00011	0.000273	CcSEcCtD
Cyclophosphamide—Anorexia—Prednisone—systemic scleroderma	0.000109	0.000269	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000109	0.000269	CcSEcCtD
Cyclophosphamide—Anaemia—Methotrexate—systemic scleroderma	0.000108	0.000268	CcSEcCtD
Cyclophosphamide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000107	0.000265	CcSEcCtD
Cyclophosphamide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000263	CcSEcCtD
Cyclophosphamide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000263	CcSEcCtD
Cyclophosphamide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000261	CcSEcCtD
Cyclophosphamide—Malaise—Methotrexate—systemic scleroderma	0.000105	0.000261	CcSEcCtD
Cyclophosphamide—Leukopenia—Methotrexate—systemic scleroderma	0.000105	0.000259	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000104	0.000258	CcSEcCtD
Cyclophosphamide—Paraesthesia—Prednisone—systemic scleroderma	0.000103	0.000254	CcSEcCtD
Cyclophosphamide—Cough—Methotrexate—systemic scleroderma	0.000102	0.000253	CcSEcCtD
Cyclophosphamide—Convulsion—Methotrexate—systemic scleroderma	0.000101	0.000251	CcSEcCtD
Cyclophosphamide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.0001	0.000248	CcSEcCtD
Cyclophosphamide—Arthralgia—Methotrexate—systemic scleroderma	9.96e-05	0.000246	CcSEcCtD
Cyclophosphamide—Chest pain—Methotrexate—systemic scleroderma	9.96e-05	0.000246	CcSEcCtD
Cyclophosphamide—Myalgia—Methotrexate—systemic scleroderma	9.96e-05	0.000246	CcSEcCtD
Cyclophosphamide—Decreased appetite—Prednisone—systemic scleroderma	9.93e-05	0.000246	CcSEcCtD
Cyclophosphamide—Fatigue—Prednisone—systemic scleroderma	9.85e-05	0.000244	CcSEcCtD
Cyclophosphamide—Discomfort—Methotrexate—systemic scleroderma	9.84e-05	0.000243	CcSEcCtD
Cyclophosphamide—Constipation—Prednisone—systemic scleroderma	9.77e-05	0.000242	CcSEcCtD
Cyclophosphamide—Confusional state—Methotrexate—systemic scleroderma	9.62e-05	0.000238	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methotrexate—systemic scleroderma	9.55e-05	0.000236	CcSEcCtD
Cyclophosphamide—Infection—Methotrexate—systemic scleroderma	9.48e-05	0.000235	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Prednisone—systemic scleroderma	9.41e-05	0.000233	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Methotrexate—systemic scleroderma	9.35e-05	0.000231	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Methotrexate—systemic scleroderma	9.23e-05	0.000228	CcSEcCtD
Cyclophosphamide—Anorexia—Methotrexate—systemic scleroderma	9.1e-05	0.000225	CcSEcCtD
Cyclophosphamide—Urticaria—Prednisone—systemic scleroderma	9.07e-05	0.000225	CcSEcCtD
Cyclophosphamide—Body temperature increased—Prednisone—systemic scleroderma	9.03e-05	0.000223	CcSEcCtD
Cyclophosphamide—Hypotension—Methotrexate—systemic scleroderma	8.92e-05	0.000221	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	8.7e-05	0.000215	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methotrexate—systemic scleroderma	8.57e-05	0.000212	CcSEcCtD
Cyclophosphamide—Dyspnoea—Methotrexate—systemic scleroderma	8.51e-05	0.000211	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Prednisone—systemic scleroderma	8.41e-05	0.000208	CcSEcCtD
Cyclophosphamide—Decreased appetite—Methotrexate—systemic scleroderma	8.3e-05	0.000205	CcSEcCtD
Cyclophosphamide—Fatigue—Methotrexate—systemic scleroderma	8.23e-05	0.000204	CcSEcCtD
Cyclophosphamide—Asthenia—Prednisone—systemic scleroderma	8.19e-05	0.000203	CcSEcCtD
Cyclophosphamide—Pain—Methotrexate—systemic scleroderma	8.16e-05	0.000202	CcSEcCtD
Cyclophosphamide—Pruritus—Prednisone—systemic scleroderma	8.08e-05	0.0002	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Methotrexate—systemic scleroderma	7.87e-05	0.000195	CcSEcCtD
Cyclophosphamide—Diarrhoea—Prednisone—systemic scleroderma	7.81e-05	0.000193	CcSEcCtD
Cyclophosphamide—Urticaria—Methotrexate—systemic scleroderma	7.58e-05	0.000188	CcSEcCtD
Cyclophosphamide—Dizziness—Prednisone—systemic scleroderma	7.55e-05	0.000187	CcSEcCtD
Cyclophosphamide—Body temperature increased—Methotrexate—systemic scleroderma	7.55e-05	0.000187	CcSEcCtD
Cyclophosphamide—Vomiting—Prednisone—systemic scleroderma	7.26e-05	0.00018	CcSEcCtD
Cyclophosphamide—Rash—Prednisone—systemic scleroderma	7.2e-05	0.000178	CcSEcCtD
Cyclophosphamide—Dermatitis—Prednisone—systemic scleroderma	7.19e-05	0.000178	CcSEcCtD
Cyclophosphamide—Headache—Prednisone—systemic scleroderma	7.15e-05	0.000177	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Methotrexate—systemic scleroderma	7.03e-05	0.000174	CcSEcCtD
Cyclophosphamide—Asthenia—Methotrexate—systemic scleroderma	6.85e-05	0.00017	CcSEcCtD
Cyclophosphamide—Nausea—Prednisone—systemic scleroderma	6.78e-05	0.000168	CcSEcCtD
Cyclophosphamide—Pruritus—Methotrexate—systemic scleroderma	6.75e-05	0.000167	CcSEcCtD
Cyclophosphamide—Diarrhoea—Methotrexate—systemic scleroderma	6.53e-05	0.000162	CcSEcCtD
Cyclophosphamide—Dizziness—Methotrexate—systemic scleroderma	6.31e-05	0.000156	CcSEcCtD
Cyclophosphamide—Vomiting—Methotrexate—systemic scleroderma	6.07e-05	0.00015	CcSEcCtD
Cyclophosphamide—Rash—Methotrexate—systemic scleroderma	6.02e-05	0.000149	CcSEcCtD
Cyclophosphamide—Dermatitis—Methotrexate—systemic scleroderma	6.01e-05	0.000149	CcSEcCtD
Cyclophosphamide—Headache—Methotrexate—systemic scleroderma	5.98e-05	0.000148	CcSEcCtD
Cyclophosphamide—Nausea—Methotrexate—systemic scleroderma	5.67e-05	0.00014	CcSEcCtD
